growth - Investors focus on revenue CAGR (20%+ required), market penetration in underpenetrated SI joint dysfunction diagnosis (estimated…
Rising rates pressure valuation multiples for unprofitable growth companies, as SI-BONE's negative FCF makes it sensitive to discount rate…
Watch on earnings: Medicare national and local coverage determination updates for SI joint fusion (CPT 27279), Quarterly U.S. procedure volume growth vs. 20% benchmark, Sales force headcount and productivity (procedures per rep per quarter).
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $232M to $268M as quarterly procedure volume growth rates and guidance - market expects 18-22% annual growth to justify valuation.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
